title: Image-guided hypofractionated radiotherapy in low-risk prostate cancer patients.
abstract: OBJECTIVE
  To evaluate efficacy and toxicity of image-guided hypofractionated radiotherapy (HFRT) in the treatment of low-risk prostate cancer. Outcomes and toxicities of this series of patients were compared to another group of 32 low-risk patients treated with conventional fractionation (CFRT).
  
  
  METHODS
  Fifty-nine patients with low-risk prostate cancer were analysed. Total dose for the prostate and proximal seminal vesicles was 60 Gy delivered in 20 fractions.
  
  
  RESULTS
  The median follow-up was 30 months. The actuarial 4-year overall survival, biochemical free survival, and disease specific survival were 100%, 97.4%, and 97.4%, respectively. Acute grade 1-2 gastrointestinal (GI) and genitourinary (GU) toxicity rates were 11.9% and 40.7%, respectively. Grade 1 GI and GU late toxicity rates were 8.5% and 13.6%, respectively. No grade ≥ 2 late toxicities were recorded. Acute grade 2-3 GU toxicity resulted significantly lower (P = 0.04) in HFRT group compared to the CFRT group. The cumulative 4-year incidence of grade 1-2 GU toxicity was significantly higher (P < 0.001) for HFRT patients.
  
  
  CONCLUSIONS
  Our study demonstrated that hypofractionated regimen provided excellent biochemical control in favorable risk prostate cancer patients. The incidence of GI and GU toxicity was low. However, HFRT presented higher cumulative incidence of low-grade late GU toxicity than CFRT.
authors.affiliation: Department of Radiation Oncology, "La Sapienza" University, Sant'Andrea Hospital of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Valeriani
authors.affiliation: Department of Radiation Oncology, "La Sapienza" University, Sant'Andrea Hospital of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Alessia
authors.initials: A
authors.lastname: Carnevale
authors.affiliation: Department of Radiation Oncology, "La Sapienza" University, Sant'Andrea Hospital of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Linda
authors.identifier: 0000-0003-1534-4386
authors.initials: L
authors.lastname: Agolli
authors.affiliation: Department of Radiation Oncology, "La Sapienza" University, Sant'Andrea Hospital of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Bonome
authors.affiliation: Department of Radiation Oncology, "La Sapienza" University, Sant'Andrea Hospital of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Adelaide
authors.initials: A
authors.lastname: Montalto
authors.affiliation: Department of Radiation Oncology, "La Sapienza" University, Sant'Andrea Hospital of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Nicosia
authors.affiliation: Department of Radiation Oncology, "La Sapienza" University, Sant'Andrea Hospital of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Mattia F
authors.initials: MF
authors.lastname: Osti
authors.affiliation: Department of Radiation Oncology, "La Sapienza" University, Sant'Andrea Hospital of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Vitaliana
authors.initials: V
authors.lastname: De Sanctis
authors.affiliation: Department of Radiation Oncology, "La Sapienza" University, Sant'Andrea Hospital of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Minniti
authors.affiliation: Department of Radiation Oncology, "La Sapienza" University, Sant'Andrea Hospital of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Riccardo
authors.initials: R
authors.lastname: Maurizi Enrici
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019583:Dose Fractionation, Radiation; D041981:Gastrointestinal Tract / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D061089:Radiotherapy, Image-Guided / Q000009:adverse effects; D012008:Recurrence; D012307:Risk Factors; D016019:Survival Analysis